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Positron emission tomography (PET) is a technique that enables im-
aging of the distribution of radiolabeled tracers designed to track biochem-
ical and molecular processes in the body after intravenous injection or
inhalation. New strategies for the use of radiolabeled tracers hold potential
for imaging gene expression in the brain during development and following
interventions. In addition, PET may be key in identifying the physiological
consequences of gene mutations associated with mental retardation. The
development of high spatial resolution microPET scanners for imaging of
rodents provides a means for longitudinal study of transgenic mouse mod-
els of genetic disorders associated with mental retardation. In this review,
we describe PET methodology, illustrate how PET can be used to delineate
biochemical changes during brain development, and provide examples of
how PET has been applied to study brain glucose metabolism in Rett syn-
drome, serotonin synthesis in autism, and GABAA receptors in Angelman’s
syndrome and Prader–Willi syndrome. Future application of PET scanning in
the study of mental retardation might include measurements of brain pro-
tein synthesis in fragile X syndrome and tuberous sclerosis complex, two
common conditions associated with mental retardation in which cellular
mechanisms involve dysregulation of protein synthesis. Mental retardation
results in life-long disability, and application of new PET technologies holds
promise for a better understanding of the biological underpinnings of men-
tal retardation, with the potential to uncover new treatment options.
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Numerous gene mutations are being identified as causalin conditions involving developmental delay and men-tal retardation. Technologies such as positron emission
tomography (PET) may be key in identifying the physiological
and biochemical consequences of these gene mutations. Under-
standing the physiological and biochemical impact of a genetic
mutation or polymorphism is essential for devising interventions
to change the course of abnormal brain development. These
PET studies may include studies in human subjects and studies
utilizing genetic animal models of human mutations resulting in
mental retardation. Studies in transgenic mouse models of hu-
man genetic disorders are now possible using PET scanners
designed for rodents [Massoud and Gambhir, 2003; Tai et al.,
2003], and new developments in “micro” PET technology to
obtain higher spatial resolution will increase the utility of this
approach in the near future [Stickel and Cherry, 2005]. In this
review, we begin by introducing the basics of the PET meth-
odology. We discuss ethical issues constraining the implemen-
tation of PET technology in developmental disorders. We then
review PET studies showing changes in glucose metabolism,
serotonin synthesis, and GABAA receptor binding during hu-
man brain development, to demonstrate the impact of the
timing of PET studies during development. We illustrate how
these same tracers have been applied in different syndromes
associated with mental retardation. Finally, we suggest how
future studies of brain protein synthesis might be informative in
elucidating altered developmental processes in two common
causes of mental retardation for which genes have been identi-
fied and cellular mechanisms involve regulation of protein syn-
thesis: Fragile X syndrome and tuberous sclerosis complex
(TSC).
PET METHODOLOGY
PET is a technique that can measure and image the
distribution of tracers that are designed to track biochemical and
molecular processes in the body after intravenous injection or
inhalation. This is accomplished by radiolabeling compounds of
interest with a positron emitting radionuclide. These short-lived
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isotopes (most frequently used isotopes
include fluorine-18 with a half-life of
110 min, carbon-11 with a half-life of 20
min, and oxygen-15 with a half-life of 2
min) emit positrons during nuclear decay
that in turn collide with surrounding
electrons, resulting in annihilation of
both particles and the release of two
high-energy (511 KeV) gamma rays. The
two gamma rays generated by a single
event travel in opposite directions and are
recorded by multiple pairs of oppositely
situated detectors that constitute the PET
camera [Hoffman and Phelps, 1986; Ter-
Pogossian, 1995]. Thus, the time course
of changes in the distribution of the ra-
diolabeled tracer in the body are re-
corded by the ring of detectors during
the radioactive decay of the radionuclide.
Using the dynamic tissue time–activity
data obtained in this manner and appro-
priate kinetic modeling of tracer behav-
ior, one can then calculate physiological
parameters of interest (for example, re-
ceptor density, glucose metabolic rate,
protein synthesis rate, etc.). Absolute
quantification and estimation of relevant
parameters of a given biochemical path-
way in a noninvasive manner distin-
guishes PET from other similar technol-
ogies such as single photon emission
computed tomography (SPECT) in
which absolute quantification is difficult.
A large number of PET radiophar-
maceuticals have been developed over
the past 30 years for the study of normal
physiological processes and for applica-
tion to the study of many disorders. In-
deed, more than 1,400 PET tracers have
been produced, and the rate of develop-
ment of new tracers seems to continue in
the exponential growth phase even today
[Iwata, 2004]. Radiolabeled tracers can
be divided into several categories. The
first group includes normal metabolic
substrates or analogs of these substrates,
such as glucose, amino acids, fatty acids,
nucleotides, and oxygen [Shiue and
Welch, 2004]. Another group of PET
tracers includes ligands that bind to pro-
teins such as receptors and transporters
[Smith et al., 2003; Gjedde et al., 2005].
Finally, newer PET probes include anti-
bodies, oligonucleotides, and tracers to
image reporter genes to monitor gene
therapy [MacLaren et al., 2000; Jain and
Batra, 2003]. The traditional PET tracers
were predominantly small molecules and
were produced using synthetic chemistry
techniques. These techniques have pro-
duced many specific tracers useful for
clinical purposes. However, increasingly,
PET radiopharmaceuticals are being pro-
duced by bioengineering techniques,
paralleling similar developments in the
drug industry [Weissleder and Mah-
mood, 2001]. The PET tracers produced
by these techniques are typically large-
molecular-weight “biotechnology probes.”
These techniques are often flexible enough to
produce “designer” probes with the desired
specificity, affinity, and other properties. Such
targeted imaging can lead to imaging precise
molecular abnormalities in humans in a rela-
tively noninvasive manner. However, these
new technologies have been predominantly
applied to disorders outside the brain, since
the blood–brain barrier bars entry of these
larger probes. Several groups of investigators
are working on strategies for facilitating brain
entry of these large-molecular-weight tracers.
For example, targeting tracers to endogenous
brain endothelial transporters such as carrier-
mediated transporters, active efflux transport-
ers, or receptor-mediated transporters has
been attempted to improve brain tracer de-
livery [for review, see Pardridge, 2005].
PET potentially can be used non-
invasively to assess gene expression either
at the mRNA or protein expression lev-
els using specific molecular imaging
probes to study the dynamic processes in
vivo in real-time in a quantitative and
noninvasive manner [Massoud and Gam-
bhir, 2003]. For example, reporter gene
imaging can be used to measure gene
expression levels [Herschman et al.,
2000; Doubrovin et al., 2004; Her-
schman, 2004]. These studies could be
invaluable in genotype–phenotype cor-
relations. When cloned into promoter/
enhancer sequences or engineered into
fusion proteins, imaging reporters can be
used to study the expression levels of any
gene product. While animal models have
tremendously advanced our understand-
ing of the molecular and pathological
phenotypic changes for a given genetic
abnormality, predicting the human be-
havioral phenotypes from the underlying
genetic changes has been less successful.
PET technology, when applied to the
study of gene expression levels, is ideally
suited to fill this gap. Most of the ad-
vances in PET using molecular imaging
probes have been made in oncology, but
similar strategies can be applied theoret-
ically to the study of mental retardation
and developmental disabilities.
ETHICAL ISSUES IN APPLYING
PET TO CHILDREN
Given the large biochemical and
physiological changes in the brain during
development, the optimal design for PET
studies in subjects with mental retardation
would be to compare experimental results
over the course of development from the group
with mental retardation to those of an
aged-matched normal control group.
However, in the PET studies published
thus far, normal control groups have not
been available. The majority of the chil-
dren were studied for a neurological (usu-
ally epilepsy) or neurodevelopmental con-
dition, and comparisons were made among
groups of children with different disorders.
This is due the to current thinking that
administration of the radiopharmaceutical
necessary for PET scanning in normal chil-
dren may be ethically unacceptable. Poten-
tial risks in performing imaging studies with
PET include pharmacological effects of
PET radiopharmaceuticals, the use of seda-
tion, and the exposure to ionizing radia-
tion. However, it should be emphasized
that PET scanning involves the administra-
tion of a single dose of the radiopharma-
ceutical in tracer quantities, indicating that
the pharmacological effects are unlikely to
be of any concern. These tracer doses typ-
ically range from 10,000- to 1,000,000-
fold lower than therapeutic doses and, in
fact, typical doses used in PET are lower
than quantities of toxins legally present in
our drinking water [Barrio et al., 2004].
Sedation may need to be employed for
many imaging procedures, particularly in
young children. Several large studies indi-
cate that the risk associated with sedation is
small and that sedation of children can be
done in a safe and highly efficacious man-
ner in a hospital radiology department us-
ing a structured sedation program modeled
after the guidelines of the American Acad-
emy of Pediatrics [Merola et al., 1995;
Egelhoff et al., 1997]. As for radiation ex-
posure, this is quite small in a typical PET
study, particularly in comparison to the ex-
posure obtained during many other clinical
radiological procedures. Ernst et al. [1998]
reviewed studies of low-level radiation ex-
posure with large sample sizes and long
follow-up and concluded that health risks
from low-level radiation could not be de-
tected above those of adverse events in
daily life. Furthermore, they found no ev-
idence that these levels of radiation were
more harmful to children than to adults.
The effective dose for a typical PET study
conveys a lifetime cancer mortality risk of
0.0005. Given that the lifetime risk of dy-
ing from cancer is 23.66 for males and
19.99 for females, this additional risk of
0.0005 is negligible.
Given the small risk of PET scan-
ning to the individual child, we raise the
issue whether it is ethical to deny ade-
quate access of PET technology for the
study of life-changing disorders of child-
hood, including those associated with
mental retardation. We suggest that the
risk to normal children over the age of
8–10 years, in which sedation is not nec-
essary, is minimal to the individual child.
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Further, we propose screening of healthy
children to identify and exclude those
children who have had a large past med-
ical exposure to radiation and strong fam-
ily history of cancer. In the future, risk
may be further minimized by prescreen-
ing for genes (such as mutations in DNA
repair enzymes) that may put certain in-
dividuals at higher risk. Strategies for es-
tablishing normal values in young chil-
dren may come from the development of
PET instrumentation to allow a larger
field of view and smaller aperture so that
dynamic imaging of normal organs can
be acquired during the same scanning
period as the target organ. Mental retar-
dation results in life-long disability, and
carefully designed PET studies will not
only enhance our understanding, but
may also lead to new treatment strategies




Normal development depends upon
the orchestrated execution of genetic de-
velopmental programs under optimal envi-
ronmental conditions. Mental retardation
occurs when there is disruption in normal
brain development. To apply PET in the
study of developmental disorders, it is
necessary to first recognize normal patterns
of brain maturation. For example, PET
studies in humans have shown significant
changes in glucose metabolism during nor-
mal brain development [Chugani et al.,
1987]. Similarly, PET studies of neuro-
transmitter synthesis [Chugani et al., 1999]
and receptor binding [Chugani et al., 2001]
have also demonstrated significant changes
during human brain development.
Glucose Metabolism
Studies of regional cerebral glucose
metabolism in human infants using PET
with the tracer 2-deoxy-2[18F]-fluoro-D-
glucose (FDG) have shown that the pat-
tern of glucose utilization undergoes dra-
matic changes in the first postnatal year.
A consistent pattern is seen in the new-
born, with the highest glucose metabolic
activity in primary sensorimotor cortex,
thalamus, brain stem, and cerebellar ver-
mis [Chugani and Phelps, 1986; Chugani
et al., 1987; Chugani, 1994; Kinnala et
al., 1996]. Intermediate levels of glucose
metabolism are present in cingulate cor-
tex, amygdala, hippocampus, and occa-
sionally the basal ganglia [Chugani, 1996,
1998]. The major portion of cerebral
cortex shows the lowest glucose metab-
olism. This neonatal pattern of glucose
metabolism, largely confined to subcor-
tical structures, is consistent with the less
complex behavior of neonates compared
to infants. Subsequently, the ontogeny of
regional brain glucose metabolism ap-
pears to follow a phylogenetic order,
with functional maturation of older ana-
tomical structures preceding that of
newer areas [Chugani and Phelps, 1986;
Chugani et al., 1987; Chugani, 1994;
Kinnala et al., 1996; Chugani, 1996,
1998]. Moreover, functional maturation
of various brain regions as depicted by a
rise in regional glucose metabolism cor-
relates well with the maturation of be-
havioral, neurophysiological, and neuro-
anatomical events in the infant. As
visuospatial and visuosensorimotor inte-
grative functions are acquired in the sec-
ond and third months of life [Bronson,
1974], and primitive reflexes become re-
organized [Andre-Thomas et al., 1960;
Parmelee and Sigman, 1983], increases in
glucose metabolism are observed in pari-
etal, temporal, and primary visual cortical
regions, frontal eye fields (Brodmann
area 8), basal ganglia, and cerebellar
hemispheres. Increasing glucose metabo-
lism in cerebral cortex during the second
and third months of life presumably re-
flects maturation of the cortex and is
consistent with the dramatic maturation
of the electroencephalogram seen during
the same period [Kellaway, 1979]. Be-
tween 6 and 8 months, the remaining
frontal cortex begins to show a matura-
tional rise in glucose metabolism, which
continues until 1 year of age. Functional
maturation of the frontal cortex begins in
the lateral and inferior portions and later
proceeds to include the medial and lastly
the dorsal prefrontal areas. Functional
maturation of these frontal cortical re-
gions coincides with the emergence of
higher cortical and cognitive abilities. By
1 year of age, the overall pattern of brain
glucose metabolism is similar to that seen
in adults. Measurement of the local cere-
bral metabolic rates of glucose utilization
(LCMRglc) in children using PET has
confirmed the findings of Kennedy and
Sokoloff [1957] that children undergo a
period during development when brain
energy demand exceeds that of adults
[Chugani et al., 1987]. Unlike the study
of Kennedy and Sokoloff [1957], which
measured global cerebral blood flow and
oxygen utilization, PET measurements of
LCMRglc showed that the magnitude of
increase over adult values is most marked
for the neocortex, intermediate for basal
ganglia and thalamus, and is probably not
present in brain stem and cerebellum. In
other words, there appears to be a hier-
archical ordering of structures in terms of
the degree to which maturational in-
creases in LCMRglc exceed adult values.
The typically low neonatal values of LC-
MRglc, which are about 30% lower than
adult rates, rapidly increase from birth
and reach adult values by about the sec-
ond year. Thereafter, LCMRglc values
continue to increase and begin to exceed
adult values during the third postnatal
year. By about 3 years, a plateau is
reached that extends until about 9–10
years; following this, there is a gradual
decline in LCMRglc to reach adult val-
ues again by about 16–18 years [Chugani
et al., 1987; Chugani, 1994, 1998]. The
relative increase of LCMRglc over adult
values, which is most pronounced in
neocortical regions between 3 and 10
years, reaches a peak LCMRglc of over
twice the LCMRglc levels seen in adults.
Serotonin Synthesis
Similar to developmental changes
shown for cerebral glucose metabolism,
ontogeny studies in nonhuman primates
also demonstrate changes in neurotrans-
mitter content and receptor binding
[Goldman-Rakic and Brown, 1982;
Lidow et al., 1991]. For example, in the
macaque, there is a steep rise in cortical
serotonin content beginning before birth
and reaching a peak at 2 months of age,
followed by a slow decline until about 3
years of age, when puberty occurs [Gold-
man-Rakic and Brown, 1982]. The same
group of investigators has reported a sim-
ilar time course for expression of seroto-
nin receptors [Lidow et al., 1991]. We
[Chugani et al., 1999] measured whole
brain serotonin synthesis capacity at dif-
ferent ages using the tryptophan analogue
-[11C]methyl-L-tryptophan (AMT) and
PET in autistic children and a compari-
son group comprised of 8 healthy non-
autistic siblings (6 males, 2 females, 2–14
years) of autistic children, as well as 16
children with epilepsy who were devel-
oping normally (9 males, 7 females, 3
months to 13 years). We obtained per-
mission to study healthy siblings of chil-
dren with autism in order to study the
broader phenotype of autism present in
many autism family members, thus pro-
viding potential benefit to the healthy
siblings who participated. For this group
of “control ” children, serotonin synthe-
sis capacity was 200% of adult values
until the age of 5 years and then declined
toward adult values. Serotonin synthesis
capacity values declined at an earlier age
in girls than in boys. These data suggest
that humans undergo a period of high
brain serotonin synthesis capacity during
childhood followed by a decline toward
adult values and that there are gender
differences.
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GABAA Receptors
An understanding of human GABAA
receptor ontogeny is highly relevant in eluci-
dating the pathophysiology of neurodevel-
opmental disorders in which GABAergic
mechanisms play a role as well as in under-
standing age-related differences in the
pharmacology of drugs acting on this sys-
tem. We have measured age-related
changes in the brain distribution of the
GABAA receptor complex in vivo using
PET in children with epilepsy under eval-
uation for surgical treatment [Chugani et
al., 2001]. PET imaging was performed
using the tracer [11C]flumazenil (FMZ), a
ligand that binds to -subunits of the
GABAA receptor. FMZ binding was quan-
tified using a two-compartment model
yielding values for the volume of distribu-
tion (VD) of the tracer in tissue. All brain
regions studied showed the highest value
for FMZ VD at the youngest age measured
(2 years), and the values then decreased
exponentially with age. Medial temporal
lobe structures, primary visual cortex, and
thalamus showed larger differences be-
tween age 2 years and adulthood (approx-
imately 50% decrease) compared to basal
ganglia, cerebellum, and other cortical re-
gions (which showed 25–40% decreases
from 2 years to adulthood). Furthermore,
subcortical regions reached adult values







Altered Glucose Metabolism in Rett
Syndrome
Rett syndrome is a progressive
neurological disorder in which deceler-
ated head growth in girls is accompanied
by mental retardation [Rett, 1966]. In
addition, girls with Rett syndrome have
characteristic stereotyped hand move-
ments, ataxia, seizures, and autistic traits.
Girls with Rett syndrome have muta-
tions in the methyl-CpG binding protein
2 (MECP2) gene located at chromosome
Xq28. Villemagne et al. [2002] studied
glucose metabolism with PET in six girls
with Rett syndrome aged 3 to 15 years of
age and compared their results to the
studies described above [Chugani and
Phelps, 1986; Chugani et al., 1987]. This
study found relatively increased glucose
metabolism in the frontal cortex of the
younger girls (3–8 years of age) studied.
The authors related this result to a post-
mortem report of increased N-methyl-D-
aspartate receptors in superior frontal gy-
rus in young Rett subjects [Blue et al.,
1999], given the coupling of cerebral
glucose metabolism to glutamate trans-
port [Magistretti et al., 1999]. In addi-
tion, glucose metabolism in Rett subjects
was relatively decreased in visual associa-
tion areas and relatively increased in the
cerebellum. These results are consistent
with the notion of developmental arrest
in girls with Rett syndrome, since this
pattern of glucose metabolism is found
during development in children less than
1 year of age [Chugani and Phelps, 1986,
Chugani et al., 1987].
Focal and Global Abnormalities of
Serotonin Synthesis in Autism
Autism is a neurodevelopmental
disorder, characterized by deficits in so-
cial interaction and communication (ver-
bal and nonverbal) and associated with
restricted, repetitive, or stereotyped be-
haviors, and is associated with mental re-
tardation in approximate 75% of cases.
To determine whether there are brain
serotonergic abnormalities in children
with autism, we have evaluated serotonin
synthesis capacity in vivo with PET, us-
ing the tryptophan analogue -[11C]m-
ethyl-L-tryptophan (AMT) as the tracer.
Our publications illustrate two funda-
mentally different types of serotonergic
abnormality in children with autism
[Chugani et al., 1997, 1999; Chandana et
al., 2005]. The first is a difference in
whole brain serotonin synthesis capacity
in autistic children compared to age-
matched nonautistic children. As de-
scribed above, serotonin synthesis capac-
ity was 200% of adult values until the
age of 5 years and then declined toward
adult values in nonautistic children. In
contrast, serotonin synthesis capacity in
autistic children increased gradually be-
tween the ages of 2 and 15 years to values
1.5 times the adult normal values [Chu-
gani et al., 1999]. These data suggested
that humans undergo a period of high
brain serotonin synthesis capacity during
early childhood and that this develop-
mental process is disrupted in autistic
children. The second type of abnormality
we have reported relates to focal abnor-
malities in brain serotonin synthesis.
Asymmetries of AMT uptake in frontal
cortex, thalamus, and cerebellum were
visualized in children with autism [Chu-
gani et al., 1997]. In addition, we mea-
sured brain serotonin synthesis in a large
group of autistic children (n  117)
with AMT PET and related these data
to handedness and language function
[Chandana et al., 2005]. Cortical AMT
uptake abnormalities were objectively
derived from small homotopic cortical
regions using a predefined cutoff asym-
metry threshold (2 SD of normal asym-
metry). Autistic children demonstrated
several patterns of abnormal cortical in-
volvement, including right cortical, left
cortical, and absence of abnormal asym-
metry. Groups of autistic children de-
fined by presence or absence and side of
cortical asymmetry differed on a measure
of language as well as handedness. Autis-
tic children with left cortical AMT de-
creases showed a higher prevalence of
severe language impairment, whereas
those with right cortical decreases
showed a higher prevalence of left and
mixed handedness. These results suggest
that global as well as focal abnormally
asymmetric development in the seroto-
nergic system could lead to miswiring of
the neural circuits specifying hemispheric
specialization.
Decreased GABAA Receptor
Binding in Angelman Syndrome
and Prader–Willi Syndrome
Angelman syndrome and Prader–
Willi syndrome result from deletions in
chromosome 15q11-q13 [for reviews see
Dykens et al., 2004; Soejima and Wag-
staff, 2005]. Deletion of the maternal
chromosome in this region results in An-
gelman syndrome, which is characterized
by severe mental retardation, epilepsy, a
puppet-like gait, and lack of speech. De-
letion of the paternal chromosome
15q11-q13 results in Prader–Willi syn-
drome, which is characterized by mild or
moderate mental retardation, hypotonia,
obesity, and genital abnormalities. This re-
gion of chromosome 15 encodes GABAA
receptor subunit genes GABRB3,
GABRA5, and GABRG3 [Wagstaff et al.,
1991; Menold et al. 2001, Buxbaum et al.,
2002]. [11C]Flumazenil PET has been used
to examine whether there are GABAA re-
ceptor binding abnormalities in patients
with Angelman syndrome and Prader–
Willi syndrome. Angelman patients with a
maternal deletion of 15q11–13 leading to
the loss of 3 subunit of the GABA recep-
tor showed significantly decreased binding
of [11C]flumazenil in frontal, parietal, hip-
pocampal, and cerebellar regions compared
to a patient whose deletion did not include
the GABRB3 gene [Holopainen et al.,
2001]. Lucignani et al. [2004] studied six
adults with Prader–Willi syndrome and
found decreased [11C]flumazenil binding in
insula and cingulate, frontal, and temporal
neocortices compared to normal control
subjects. These studies demonstrate the
utility of PET in elucidating the functional
consequence of specific genetic abnormal-
ities.
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FUTURE APPLICATIONS:
ALTERED PROTEIN
SYNTHESIS IN FRAGILE X
SYNDROME AND TUBEROUS
SCLEROSIS COMPLEX
Protein synthesis can be measured
with PET using radiolabeled amino ac-
ids. Although a number of amino acids
have been radiolabeled for PET studies in
oncology, 1-[11C]L-leucine is the most
suitable amino acid for quantifying pro-
tein synthesis rate in brain because of its
theoretically straightforward kinetic mod-
eling. This method is based upon the
1-[14C]L-leucine autoradiographic method
described and validated by Smith et al.
[1984, 1988]. This method was adapted
for PET with 1-[11C]L-leucine in hu-
mans 20 years ago [Phelps et al., 1984;
Hawkins et al., 1989], but has not been
widely applied due to difficulties with the
chemical synthesis of the radiotracer and
the lack of a method to estimate the
fraction of amino acid pool derived from
protein breakdown in the tissue [Smith et
al., 1988], leading to an underestimation
of the rate of protein synthesis. The es-
timate of the tissue-derived amino acid
pool was particularly a problem for the
study of developmental disorders, since
the amount of brain amino acid recycling
was reported to change as a function of
age [Sun et al., 1995]. Both the chemistry
and kinetic modeling problems have re-
cently been resolved [Schmidt et al.,
2005; Smith et al., 2005; Mu et al. 2005],
and therefore measurement of protein
synthesis in certain types of mental retar-
dation involving genes regulating protein
synthesis may provide important infor-
mation about how these mutations affect
protein synthesis at different points dur-
ing brain development and in different
brain regions.
Fragile X Syndrome
Fragile X syndrome, the most
common genetic disorder associated with
mental retardation, is caused by a repeat
expansion of CGG trinucleotide in the
5-untranslated region of the gene fragile
X mental retardation-1 (Fmr1) [Verkerk
et al., 1991]. The presence of the ex-
panded repeats in Fmr1 results in meth-
ylation and transcriptional inactivation of
the gene, leading to the reduction of
fragile X mental retardation protein
(FMRP). There is evidence that FMRP
inhibits translation in synapses through
interactions with mRNA [Li et al., 2001]
and inhibition of the assembly of the 80S
ribosome on mRNAs [Laggerbauer et
al., 2001]. Qin et al. [2005] have studied
cerebral protein synthesis in the Fmr1
null mouse model of fragile X using the
quantitative 1-[14C]L-leucine autoradio-
graphic method. In this study, cerebral
protein synthesis in Fmr1-null adult mice
was compared to wild-type mice at 4 and
6 months of age. They found regional
selective elevations in protein synthesis in
the Fmr1 mice compared to wild-type
mice at both ages, consistent with the
role of FMRP as a suppressor of protein
synthesis. Elevated protein synthesis was
most pronounced in hippocampus, thal-
amus, hypothalamus, and brain stem.
Qin et al. [2005] related their results to
behavioral features in fragile X and in the
Fmr1-null mouse, including learning and
memory deficits, increased sensory sensi-
tivity, autistic behaviors, parasympathetic
dysregulation, hyperarousal, and hyper-
activity. The examination of this mouse
model with microPET would allow fur-
ther insights into the role of FMRP
during brain development. Moreover,
microPET studies would allow the longi-
tudinal study of the same animal during
development. In addition, these animal
experiments provide the rationale for
measuring cerebral protein synthesis in
humans with fragile X syndrome using
1-[11C]L-leucine with PET.
Tuberous Sclerosis Complex
Tuberous sclerosis complex is an
autosomal dominant inherited disorder,
now known to result from mutations in
at least two different genes, TSC1 [Fryer
et al., 1987; van Slegtenhorst et al., 1997]
and TSC2 [Kandt et al., 1992]. The neu-
rological problems associated with TSC
range from mild to severe, and include
epilepsy, which is often resistant to phar-
macological treatment, developmental
delay, and cognitive problems of varying
severity (for review, see Curatolo et al.,
2002]. Molecular and biochemical stud-
ies have shown that tuberin and hamar-
tin, the protein products of TSC1 and
TSC2 genes, are regulators of the insulin
signaling pathway. Specifically, there is
evidence that tuberin and hamartin form
a dimer, which negatively regulates
Rheb (Ras homolog enriched in brain), a
positive regulator of mTOR, which is a
constituent of the insulin/phosphotidyl
inositol 3-kinase (PI3K) pathway (for re-
views see Manning and Cantley, 2003;
Kwiatkowski, 2003]. Mutations of TSC1
and TSC2 result in a release of inhibition
of mTOR resulting in an increase in pro-
tein synthesis and cell growth. Thus, there
is rationale for studying cerebral protein
synthesis in TSC, particularly in children
during the period of maximal brain
growth.
CONCLUSION
There are numerous probes for
biochemical and molecular imaging with
PET, yet only a small number of these
probes have been applied to the study of
mental retardation. Rational application
of radiopharmaceuticals to the study of
mental retardation can provide important
insight into the functional consequences
of certain gene mutations in the devel-
oping brain. Identifying the patterns and
quantifying the physiological and bio-
chemical abnormalities in the brains of
mentally retarded subjects will yield im-
portant biological markers that can be
used to monitor disease progression and
response to therapy. It is also conceivable
that new therapeutic strategies may
emerge as a result of these studies with
PET. f
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